Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.52 |
| ▸ | CTSK | P43235 | 4/20 | 0.52 |
| ▸ | PPARA | Q07869 | 3/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.52 |
| ▸ | BCL2 | P10415 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | KLK7 | P49862 | 1/20 | 0.48 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17724519 | 0.92 | CTSS (0.60) | CTSSCTSKPPARASYKCTSL | |
| SCHEMBL23837230 | 0.92 | CTSS (0.60) | CTSSCTSKPPARASYKCTSL | |
| SCHEMBL4689229 | 0.91 | CTSS (0.53) | CTSSCTSKPPARASYKCTSL | |
| SCHEMBL9042226 | 0.91 | CTSS (0.53) | CTSSCTSKPPARASYKCTSL | |
| SCHEMBL4689227 | 0.91 | CTSS (0.53) | CTSSCTSKPPARASYKCTSL | |
| SCHEMBL3379320 | 0.89 | CTSS (0.51) | CTSSCTSKPPARASYKCTSL | |
| SCHEMBL192406 | 0.89 | CTSS (0.54) | CTSSCTSKPPARASYKBCL2 | |
| SCHEMBL192405 | 0.89 | CTSS (0.54) | CTSSCTSKPPARASYKBCL2 | |
| SCHEMBL13808582 | 0.86 | CTSS (0.54) | CTSSCTSKBCL2CTSLCYP3A4 | |
| SCHEMBL5558475 | 0.84 | CTSS (0.63) | CTSSCTSKLMNAGAACTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | CENGENT THERAPEUTICS (US) | 2007-08-23 | — | — | US | disclosed |
| WO-2005027856-A2 | INHIBITORS OF ANTHRAX LETHAL FACTOR | CENGENT THERAPEUTICS (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | APAF1, ANTXR2, LITAF | CTSS 596/4885CTSK 306/4885PPARA 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.